Home/Biosimilar Atlas/Companies/Tanvex BioPharma

Tanvex BioPharma

Biosimilar developer, Taiwan. 1 development product across 1 molecule: filgrastim.

First approval in the Atlas: Oct 2021, Nypozi, filgrastim (HC)
FDAproducts approved1
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product2 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
FilgrastimNypozi TX01Jun 2024···Oct 2021··2/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Tanvex BioPharma, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Cadila PharmaceuticalsOne shared molecule: filgrastim2 molecules in its portfolioCuraTeQ BiologicsOne shared molecule: filgrastim4 molecules in its portfolioFuji PharmaOne shared molecule: filgrastim5 molecules in its portfolioGennova BiopharmaceuticalsOne shared molecule: filgrastim2 molecules in its portfolioIntas PharmaceuticalsOne shared molecule: filgrastim12 molecules in its portfolioKashiv BioSciencesOne shared molecule: filgrastim2 molecules in its portfolio

Chronology

Compare Tanvex BioPharma with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.